August 18, 2022

Auvelity® (bupropion and dextromethorphan), made by Axsome, has been approved for the treatment of major depressive disorder (MDD) in adults.

  • Auvelity is used to treat Major Depressive Disorder (MDD), in adults.
  • Recommended dosing is one tablet once daily in the morning for three days, then an increase to the maximum recommended dosage of one tablet twice daily, separated by at least 8 hours.
    • Each extended-release tablet contains dextromethorphan hydrobromide 45 mg and bupropion hydrochloride 105 mg.
  • Axsome Therapeutics has not yet set a price for Auvelity, but costs are expected to exceed $1,000 per year.
August 18, 2022

U.S. FDA Approves First Cetrotide Generic

Read More
August 17, 2022

Zynteglo Approved as Gene Therapy for Rare Blood Disorder

Read More